GlaxoSmithKline Pharmaceuticals Limited Stock price

Equities

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
1,943 INR +3.26% Intraday chart for GlaxoSmithKline Pharmaceuticals Limited -2.90% +2.41%
Sales 2024 * 33.65B 404M Sales 2025 * 36.49B 438M Capitalization 329B 3.95B
Net income 2024 * 6.06B 72.76M Net income 2025 * 7.68B 92.14M EV / Sales 2024 * 9.78 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 9.02 x
P/E ratio 2024 *
48.3 x
P/E ratio 2025 *
42.9 x
Employees 3,680
Yield 2024 *
1.56%
Yield 2025 *
1.62%
Free-Float 24.42%
More Fundamentals * Assessed data
Dynamic Chart
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14% MT
Glaxosmithkline Pharmaceuticals Limited Appoints Aparajita Mukherjee Rajput, Technology Lead CI
GlaxoSmithKline Pharmaceuticals Sees Sharp Decline in Fiscal Q3 Consolidated Net Profit MT
GSK India arm's Q3 profit falls on government price cap RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Sunder Ramachandran as Head of Commercial Excellence, Effective 12 January 2024 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Abhinav Kashyap as Pharma Technology Lead CI
GSK's India unit posts Q2 profit rise on strong vaccine demand RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Appoints Omkar Parnandiwar as Head of Omnichannel, Effective November 1, 2023 CI
Glaxosmithkline Pharmaceuticals Records Rise in Fiscal Q1 Consolidated Net Profit MT
India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Samsung Biologics unveils $920 mln manufacturing deals for Pfizer RE
A son died, his parents tried to sue. How U.S. courts protect Big Pharma RE
More news

Latest transcript on GlaxoSmithKline Pharmaceuticals Limited

1 day+3.26%
1 week-2.90%
Current month-10.54%
1 month-10.45%
3 months+7.28%
6 months+27.37%
Current year+2.41%
More quotes
1 week
1 872.15
Extreme 1872.15
1 994.90
1 month
1 872.15
Extreme 1872.15
2 262.00
Current year
1 872.15
Extreme 1872.15
2 649.95
1 year
1 228.00
Extreme 1228
2 649.95
3 years
1 228.00
Extreme 1228
2 649.95
5 years
1 046.40
Extreme 1046.4
2 649.95
10 years
1 020.00
Extreme 1020
2 649.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 22-11-30
Director of Finance/CFO - 22-03-31
Compliance Officer - -
Members of the board TitleAgeSince
Chairman 70 19-03-31
Director/Board Member 64 22-05-15
Director/Board Member 74 15-03-29
More insiders
Date Price Change Volume
24-03-28 1,943 +3.26% 18 731
24-03-27 1,882 -2.22% 11,954
24-03-26 1,924 -1.98% 8,662
24-03-22 1,963 -1.36% 7,903
24-03-21 1,991 -0.52% 6,833

Delayed Quote Bombay S.E., March 28, 2024 at 06:00 am EDT

More quotes
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1,943 INR
Average target price
2,141 INR
Spread / Average Target
+10.20%
Consensus
  1. Stock
  2. Equities
  3. Stock GlaxoSmithKline Pharmaceuticals Limited - Bombay S.E.